Camlin Fine Sciences Limited (532834) Earnings Call Transcripts
Camlin Fine Sciences Limited's Latest Earnings Call - Q4 FY2026
In Q4 FY '26, Camlin Fine Sciences Limited reported revenue of INR 424 crores, contributing to a total annual revenue of INR 1,723 crores, which reflects a decrease of INR 54 crores year-over-year. The company faced significant challenges, including a 20% impact on sales due to shipment delays and increased raw material costs. Management maintained guidance for FY '27, indicating confidence in the blends business and improved realizations in vanillin despite ongoing geopolitical tensions.
Reported metrics
| Metric | Value |
|---|---|
| Q4 Revenue | INR 424 crores (miss) |
| Total FY '26 Revenue | INR 1,723 crores (miss) |
| Blends Revenue Growth | 17% (miss) |
| Vanillin Average Realization | $12.5 (positive) |
| Q4 EBITDA | INR 21 crores (inline) |
| Gain from Discontinued Operations | INR 100 crores (positive) |
Guidance from management
Management maintained their revenue guidance for FY '27, expecting to achieve between INR 2,200 to 2,400 crores, driven by growth in the blends business and improved vanillin realizations.
What management said
Thank you. Ladies and gentlemen, welcome to the quarter's earnings call. We know your time is precious, so we will immediately begin the relevant portion. You will note amongst all the noise that is happening around the world that we have been on a very consistent strategy implementation for the last 2 years, 3 years, and you'll see the progress in the numbers and in the explanations. So without anything more, I'll h...
Yes. So diphenol is the product which we manufacture. Diphenol is nothing but hydrogen and category. I was talking about the raw material phenol, which was generally INR 85 to last -- just before the -- now it has gone up to INR 150. So naturally, the cost of production of our product, hydrogen and category have drastically increased.
What analysts pressed on
Analysts expressed concerns regarding the impact of geopolitical tensions on supply chains and pricing pressures. There were also questions about the sustainability of margins given rising raw material costs and the company's ability to manage liquidity amid increased debt levels.
Main topics on the call
- Revenue Impact from Supply Chain Issues — Management noted that 'this quarter, the sale was impacted by around 20% due to delay in shipments, lack of ships and increased voice time to our markets across the globe.' This disruption has affected working capital cy...
- Blends Business Performance — The blends segment showed steady growth, achieving a 17% increase, slightly below the 20% target. Management stated, 'we have maintained a steady growth' and expressed confidence in future performance due to strategic sh...
- Vanillin Business Outlook — Management highlighted an increase in average realization for vanillin from 'sub-11 to more than $12.5' in Q4, with expectations for further growth due to reduced tariffs. They anticipate a strong order book for the upco...
- Cost Management and EBITDA — Despite facing increased costs, management reported an EBITDA of INR 21 crores, or 5%. They indicated that 'overall costs also remain under control,' but acknowledged that 'currency fluctuations will impact the business....
Read the full Camlin Fine Sciences Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Camlin Fine Sciences Limited
Camlin Fine Sciences Limited (532834) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on BSE and is based in IN. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 27 calls on record spanning February 10, 2020 to August 11, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 Camlin Fine Sciences Limited earnings call transcripts on record, spanning February 10, 2020 to August 11, 2026. Based on this history, Camlin Fine Sciences Limited reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.